Allergan to pay $15M fine for not disclosing 2014 merger talks in timely manner & more— 6 GI company key notes

Here are six updates on GI companies to note:

Austin, Texas-based Apollo Endosurgery found its next chief medical officer in gastroenterologist Christopher Gostout, MD. Dr. Gostout has more than 30 years experience in the gastroenterology and hepatology fields at the Rochester, Minn.-based Mayo Clinic.

The U.S. Securities and Exchange Commission fined Parsippany-Troy Hills, N.J.-based Allergan $15 million for failing to disclose its 2014 merger talks with Actavis, also based in Parsippany-Troy Hills.

Allergan's CEO Brent Saunders aligned itself with President-elect Donald Trump. Mr. Saunders told Reuters that the company aligned with the "priorities of the incoming Trump administration."

Connecticut-based medical device developer Lumendi added James Soares as its vice president of sales and Yukio Nakajima as its new senior director of business development. Mr. Nakajima has more than 30 years of experience in the gastroenterology-facing medical device field.

New York's Faruqi & Faruqi, a national securities law firm, launched a legal investigation into the board of directors of Cambridge, Mass.-based Ariad Pharmaceuticals ahead of its potential sale to Japan's Takeda for $5.2 billion. Takeda is primarily acquiring Ariad's leukemia drug, Iclusig. Takeda expects the drug to generate between $170 million to $180 million in sales.

Irving, Texas-based Vizient awarded El Segundo, Calif.-based Karl Stroz Endoscopy America an innovative technology designation. Vizient awarded the designation because of the company's D-Light C Photodynamic Diagnostic system. The system detects and manages non-muscle invasive bladder cancer.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast